RT Journal Article
SR Electronic
T1 Why the SARS-CoV-2 antibody test results may be misleading: insights from a longitudinal analysis of COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.08.20245894
DO 10.1101/2020.12.08.20245894
A1 Jorg Taubel
A1 Samuel Thomas Cole
A1 Christopher S. Spencer
A1 Anne Freier
A1 Dorothée Camilleri
A1 Ulrike Lorch
YR 2020
UL http://medrxiv.org/content/early/2020/12/11/2020.12.08.20245894.1.abstract
AB To estimate the effectiveness of vaccines in development, a robust mechanism is required to understand immunity, risks of reinfection and measure the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and how this may change over time. This study is a longitudinal analysis of COVID-19 infection rates using PCR, membrane immunoassay and chemiluminescent microparticle immunoassay (CMIA) diagnostic tests. Our data confirm that antibody levels wane in the three months after symptom onset. Comparison of the three methods used suggests that quantitative CMIA testing may exaggerate numbers of COVID-19 negative individuals.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialIRAS ID: 281788Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This brief report communicates results taken from a study reviewed and given favourable opinion by NRES Committee (West Midlands - Edgbaston).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available upon request.